425: Cyclacel Reports Q2 2025 Results, Announces Strategic Merger

Cyclacel Pharmaceuticals announced its second quarter 2025 financial results, highlighted by a strategic share exchange agreement with FITTERS Diversified Berhad and a $3 million private placement.

Summary

• Net loss for the second quarter of 2025 was $1.3 million, a significant reduction from $3.3 million for the same period in 2024.
• Cash and cash equivalents totaled $4.3 million as of June 30, 2025, an increase from $3.2 million as of December 31, 2024.
• Entered into a share exchange agreement with FITTERS Diversified Berhad, where FITTERS Sdn. Bhd. will become a wholly-owned subsidiary of Cyclacel in exchange for approximately 19.99% of Cyclacel's common stock.
• The share exchange agreement was amended to include an additional $1,000,000 cash payment to Fitters Parent at the closing of the transaction.
• Completed a private placement of 3,000,000 shares of Series F Convertible Preferred Stock at $1.00 per share, generating aggregate gross proceeds of $3,000,000.
• Implemented a one-for-fifteen reverse stock split effective July 7, 2025, to meet The Nasdaq Capital Market's share bid price requirements.
• Research and development expenses decreased to $0.1 million for Q2 2025 from $2.0 million for Q2 2024, primarily due to the liquidation of the UK subsidiary, Cyclacel Limited, on January 24, 2025.
• General and administrative expenses decreased by $0.4 million to $1.2 million for Q2 2025 from $1.6 million for Q2 2024.
• No United Kingdom research & development tax credits were received in Q2 2025, compared to $0.4 million in Q2 2024, following the liquidation of the UK subsidiary.
• Net cash used in operating activities was $1.1 million for the three months ended June 30, 2025.

Sentiment

Score: 3

Explanation: While the net loss decreased and cash increased due to a capital raise, the underlying operational performance shows a significant reduction in R&D activity due to subsidiary liquidation, a very short cash runway, and the necessity of a reverse stock split to maintain Nasdaq listing. The strategic acquisition, while potentially diversifying, comes with increased costs and an extended timeline, indicating challenges.

Positives

• Net loss significantly decreased to $1.3 million in Q2 2025 from $3.3 million in Q2 2024.
• Cash and cash equivalents increased to $4.3 million as of June 30, 2025, from $3.2 million at December 31, 2024, bolstered by a capital raise.
• Successfully completed a $3.0 million private placement of Series F Convertible Preferred Stock, strengthening the cash position.
• Entered into a strategic share exchange agreement with FITTERS Diversified Berhad, aiming to diversify the business.
• General and administrative expenses decreased by $0.4 million due to lower operating costs under current management.

Negatives

• The significant decrease in net loss is largely attributable to the cessation of the transcriptional regulation program and the liquidation of the UK subsidiary, Cyclacel Limited, rather than improved core operational profitability.
• The liquidation of the UK subsidiary resulted in the loss of eligibility for United Kingdom research & development tax credits.
• Research and development expenditure for plogosertib decreased, indicating a potential slowdown or reduced focus on this program.
• A one-for-fifteen reverse stock split was implemented to meet Nasdaq bid price requirements, often a sign of struggling stock performance and investor confidence.
• The share exchange agreement with Fitters Parent was amended to include an additional $1,000,000 cash payment, increasing the cost of the acquisition.
• The Final Date for the Fitters transaction was extended to September 30, 2025, suggesting potential delays or complications in closing.
• Current cash resources are estimated to fund planned expenditure only into the fourth quarter of 2025, indicating a short cash runway and potential need for further financing.

Risks

• Product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• Clinical trials may encounter difficulties in enrolling sufficient participants.
• There is a risk of not obtaining regulatory approval to market product candidates.
• The company relies on outside financing to meet its capital requirements, posing a risk if funding is not secured.
• Reliance on collaborative partners for further clinical trials, development, and commercialization of product candidates introduces dependency risks.
• The company's ability to regain and maintain compliance with Nasdaq's continued listing requirements is uncertain.
• Market and other conditions could cause actual results to differ materially from forward-looking statements.

Future Outlook

Current cash resources are estimated to fund planned expenditure into the fourth quarter of 2025. The company continues to explore and develop an alternative salt, oral formulation with improved bioavailability for plogosertib. A special meeting is scheduled for September 4, 2025, to vote on the approval of the share exchange transaction with FITTERS Diversified Berhad.

Management Comments

• Current management has achieved lower operating costs for the company.
• We continue to explore and develop an alternative salt, oral formulation with improved bioavailability for plogosertib.

Industry Context

NA

Management Changes

Stakeholder Impact

• Shareholders: Potential for dilution from convertible preferred stock and warrants, future dilution from the Fitters transaction (19.99% of common stock), impact of reverse stock split on share count and price, and potential for business diversification.
• Employees: Liquidation of the UK subsidiary implies job losses or restructuring in that region.
• Creditors: Improved cash position from the capital raise may reduce immediate liquidity concerns, but the short cash runway remains a concern.
• Customers/Patients: Reduced R&D activity, particularly the cessation of the transcriptional regulation program, may impact the future product pipeline and availability of new treatments.

Next Steps

• A special meeting is scheduled for September 4, 2025, to vote for approval of the share exchange transaction with FITTERS Diversified Berhad.
• Continued exploration and development of an alternative salt, oral formulation with improved bioavailability for plogosertib.
• Closing of the share exchange transaction with FITTERS Diversified Berhad by September 30, 2025.

Key Dates

Recommendation

The company is in a transitional phase, marked by a strategic acquisition and a recent capital raise that improved its immediate cash position. However, the underlying operational performance shows a significant reduction in R&D, a very short cash runway, and the necessity of a reverse stock split to maintain Nasdaq listing. The success of the Fitters acquisition and its integration, along with the company's ability to secure further funding and advance its remaining drug candidates, are critical unknowns. Investors should hold to assess the execution of the new strategy and future financial stability.

Keywords

Biopharmaceutical, Oncology, Hematology, PLK1 inhibitor, Plogosertib, Nasdaq, Reverse Stock Split, Share Exchange, Private Placement, Q2 Earnings, Financial Results, Corporate Governance, Cyclacel Pharmaceuticals, FITTERS Diversified Berhad